nach oben

Erschienen in:

04.02.2021 | Original Article

Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma

verfasst von: Jianhan Huang, Meijun Zheng, Zongliang Zhang, Xin Tang, Yaxing Chen, Aijun Peng, Xingchen Peng, Aiping Tong, Liangxue Zhou

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 9/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

T cell with chimeric antigen receptors (CAR-T) has presented remarkable efficacy for blood cancer as an emerging immunotherapy. However, for solid tumors, the therapeutic efficacy is much impaired due to the lack of infiltration and persistence of CAR-T in tumor tissue. Thus, we constructed an interleukin-7-loaded oncolytic adenovirus and combined the use of oncolytic virus and CAR-T to improve the therapeutic outcome.

Methods

We constructed an interleukin-7-loaded oncolytic adenovirus (oAD-IL7) and a B7H3-targeted CAR-T and explored the efficacy of the single use of oAD-IL7, B7H3-CAR-T, or the combined therapy for glioblastoma in vitro and in vivo. The improved CAR-T anti-tumor efficacy was evaluated according to the proliferation, survival, persistence, exhaustion of T cells, and tumor regression.

Results

Constructed oAD-IL7 and B7H3-CAR-T presented moderate cytotoxicity during in vitro study, but failed to induce a thorough and persistent anti-tumor therapeutic efficacy in vivo. The combination of oAD-IL7 and B7H3-CAR-T in vitro resulted in enhanced T cell proliferation and reduced T cell apoptosis. The joint efficacy was further confirmed using tumor-bearing xenograft mice. During in vivo study, the mice treated with both oAD-IL7 and B7H3-CAR-T showed prolonged survival and reduced tumor burden. According to the ex vivo study, oAD-IL7 improved the proliferation and persistence of tumor-infiltrating B7H3-CAR-T, but failed to reverse the exhaustion.

Conclusions

Our results indicated that oAD-IL7 is a promising auxiliary therapy to improve the therapeutic efficacy of B7H3-CAR-T in glioblastoma by providing the activating signals for tumor-infiltrating T cells. Our results also lay the basis for the future clinical trials for the combination of IL7-loaded oncolytic adenovirus and CAR-T therapy for glioblastoma.

Nur mit Berechtigung zugänglich

Pagel JM, West HJ (2017) Chimeric antigen receptor (CAR) T-cell therapy. JAMA Oncol 11:1595CrossRef

Calmes-Miller J (2018) FDA approves second CAR T-cell therapy. Cancer Discov 1:5–6

Li J, Li W, Huang K, Zhang Y, Kupfer G, Zhao Q (2018) Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward. J Hematol Oncol 1:22CrossRef

Hegde PS, Chen DS (2020) Top 10 challenges in cancer immunotherapy. Immunity 1:17–35CrossRef

Grosser R, Cherkassky L, Chintala N, Adusumilli PS (2019) Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell 5:471–482CrossRef

Ma X, Shou P, Smith C, Chen Y, Du H, Sun C, Porterfield Kren N, Michaud D, Ahn S, Vincent B et al (2020) Interleukin-23 engineering improves CAR T cell function in solid tumors. Nat Biotechnol 4:448–459CrossRef

Harrington K, Freeman DJ, Kelly B, Harper J, Soria JC (2019) Optimizing oncolytic virotherapy in cancer treatment. Nat Rev Drug Discov 9:689–706CrossRef

Hemminki O, Dos Santos JM, Hemminki A (2020) Oncolytic viruses for cancer immunotherapy. Journal of Hematol Oncol 1:84CrossRef

Twumasi-Boateng K, Pettigrew JL, Kwok YYE, Bell JC, Nelson BH (2018) Oncolytic viruses as engineering platforms for combination immunotherapy. Nat Rev Cancer 7:419–432CrossRef

10.

Ge Y, Wang H, Ren J, Liu W, Chen L, Chen H, Ye J, Dai E, Ma C, Ju S et al (2020) Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety. J Immunother Cancer 8(1):e000710CrossRef

11.

Nakao S, Arai Y, Tasaki M, Yamashita M, Murakami R, Kawase T, Amino N, Nakatake M, Kurosaki H, Mori M et al (2020) Intratumoral expression of IL7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade. Sci Transl Med. https://doi.org/10.1126/scitranslmed.aax7992

12.

Perna SK, Pagliara D, Mahendravada A, Liu H, Brenner MK, Savoldo B, Dotti G (2014) Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition. Clin Cancer Res 1:131–139CrossRef

13.

Shum T, Omer B, Tashiro H, Kruse RL, Wagner DL, Parikh K, Yi Z, Sauer T, Liu D, Parihar R et al (2017) Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells. Cancer Discov 11:1238–1247CrossRef

14.

Adachi K, Kano Y, Nagai T, Okuyama N, Sakoda Y, Tamada K (2018) IL7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol 4:346–351CrossRef

15.

Tang X, Zhao S, Zhang Y, Wang Y, Zhang Z, Yang M, Zhu Y, Zhang G, Guo G, Tong A et al (2019) B7–H3 as a novel CAR-T therapeutic target for glioblastoma. Mol Ther Oncol 14:279–287CrossRef

16.

Li X, Liu Y, Wen Z, Li C, Lu H, Tian M, Jin K, Sun L, Gao P, Yang E et al (2010) Potent anti-tumor effects of a dual specific oncolytic adenovirus expressing apoptin in vitro and in vivo. Mol Cancer 9:10CrossRef

17.

Mescher MF, Curtsinger JM, Agarwal P, Casey KA, Gerner M, Hammerbeck CD, Popescu F, Xiao Z (2006) Signals required for programming effector and memory development by CD8+ T cells. Immunol Rev 211:81–92CrossRef

18.

Zhou J, Jin L, Wang F, Zhang Y, Liu B, Zhao T (2019) Chimeric antigen receptor T (CAR-T) cells expanded with IL7/IL-15 mediate superior antitumor effects. Protein Cell 10:764–769CrossRef

19.

Sidaway P (2018) CNS cancer: Oncolytic adenovirus effective in patients with glioblastoma. Nat Rev Clin Oncol 5:266CrossRef

20.

Qian C, Liu XY, Prieto J (2006) Therapy of cancer by cytokines mediated by gene therapy approach. Cell Res 2:182–188CrossRef

21.

Wing A, Fajardo CA, Posey AD, Shaw C, Da T, Young RM, Alemany R, June CH, Guedan S (2018) Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager. Cancer Immunol Res 5:605–616CrossRef

22.

Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, Rietberg SP, Linde MH, Xu P, Rota C et al (2019) CAR T cells targeting B7–H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin Cancer Res 8:2560–2574CrossRef

23.

Flem-Karlsen K, Fodstad Ø, Tan M, Nunes-Xavier CE (2018) B7–H3 in cancer—beyond immune regulation. Trends in Cancer 6:401–404CrossRef

24.

Zhang Z, Jiang C, Liu Z, Yang M, Tang X, Wang Y, Zheng M, Huang J, Zhong K, Zhao S et al (2020) B7-H3-Targeted CAR-T Cells Exhibit Potent Antitumor Effects on Hematologic and Solid Tumors. Mol Ther Oncol 17:180–189CrossRef

25.

Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, Ostberg JR, Blanchard MS, Kilpatrick J, Simpson J et al (2016) Regression of glioblastoma after chimeric antigen receptor T-cell therapy. New Engl J Med 26:2561–2569CrossRef

26.

Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D, Robertson C, Gray TL, Diouf O, Wakefield A et al (2017) HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial. JAMA Oncol 8:1094–1101CrossRef

27.

Cervera-Carrascon V, Siurala M, Santos JM, Havunen R, Tähtinen S, Karell P, Sorsa S, Kanerva A, Hemminki A (2018) TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade. Oncoimmunology 5:e1412902CrossRef

28.

Wang P, Li X, Wang J, Gao D, Li Y, Li H, Chu Y, Zhang Z, Liu H, Jiang G et al (2017) Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. Nat Commun 1:1395CrossRef

29.

Fajardo CA, Guedan S, Rojas LA, Moreno R, Arias-Badia M, de Sostoa J, June CH, Alemany R (2017) Oncolytic adenoviral delivery of an EGFR-targeting T-cell engager improves antitumor efficacy. Can Res 8:2052–2063CrossRef

30.

Porter CE, Rosewell Shaw A, Jung Y, Yip T, Castro PD, Sandulache VC, Sikora A, Gottschalk S, Ittman MM, Brenner MK et al (2020) Oncolytic adenovirus armed with BiTE, cytokine, and checkpoint inhibitor enables CAR T cells to control the growth of heterogeneous tumors. Mol Ther 5:1251–1262CrossRef

31.

Ahmed M, Cheng M, Zhao Q, Goldgur Y, Cheal SM, Guo HF, Larson SM, Cheung NK (2015) Humanized affinity-matured monoclonal antibody 8H9 has potent antitumor activity and binds to FG loop of tumor antigen B7–H3. J Biol Chem 290(50):30018–30029. https://doi.org/10.1074/jbc.M115.679852CrossRefPubMedPubMedCentral

Titel: Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma
verfasst von: Jianhan Huang
Meijun Zheng
Zongliang Zhang
Xin Tang
Yaxing Chen
Aijun Peng
Xingchen Peng
Aiping Tong
Liangxue Zhou
Publikationsdatum: 04.02.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 9/2021
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-021-02856-0

Neu im Fachgebiet Onkologie

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

23.05.2024 Leitsymptome in der Hausarztpraxis Nachrichten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma